KNSA Kiniksa Pharmaceuticals Ltd: רווח למניה בשנים עשר החודשים האחרונים

Kiniksa Pharmaceuticals (KNSA) minimizes risks by developing therapies for rare immune and cardiovascular pathologies. Sales growth of its pericarditis drug creates current momentum, while pipeline expansion establishes future catalysts. An efficient injection supply chain ensures stable margins. Net income per share over the last four quarters visualizes the return on innovation, where the value of 1.30 reflects this status.
פילוחים אנליטיים ודוחות נתונים של חברת Kiniksa Corp (KNSA)

Net income per share over 12 months reflects the actual yield of a single security by dividing the final financial result by the total number of issued shares to evaluate capital efficiency. By analyzing the 12-month net income per share snapshot, an investor can see how the diversified drug portfolio of Kiniksa Pharmaceuticals (KNSA) targeting rare pathologies transforms clinical successes into a sustainable cash flow.